Embedded Files
TACROLIMUS VERSUS CYCLOSPORINE IN LOW IMMUNOLOGICAL RISK PATIENTS AFTER KIDNEY TRANSPLANTATION INDUCTED BY ANTI-THYMOCYTE GLOBULIN
TACROLIMUS VERSUS CYCLOSPORINE IN LOW IMMUNOLOGICAL RISK PATIENTS AFTER KIDNEY TRANSPLANTATION INDUCTED BY ANTI-THYMOCYTE GLOBULIN
Chovin Nawzad Ali a, Dana Ahmed Sharif b , and Safa Ezadin Almukhtar c
a Nephrology Board Trainee, Ministry of Health, Kurdistan Region,Iraq.
b College of Medicine, University of Sulaimani, University of Sulaimani, Kurdistan Region, Iraq.
c College of Medicine, Hawler Medical University. Hawler, Kurdistan Region, Iraq.
Submitted: 6/7/2021; Accepted: 12/1/2022; Published: 21/3/2022
DOI Link: https://doi.org/10.17656/jsmc.10339
ABSTRACT
Background
Global increase in the incidence of end-stage renal disease has necessitated the performance of kidney transplantation for many patients. To minimize the possibility of renal allograft failure and maintain graft function. Kidney transplant recipients are typically given immunosuppressive drugs such as tacrolimus and Cyclosporine in combination with other drugs.
Objectives
The present study was carried out to compare the effectiveness of tacrolimus versus Cyclosporine.
Patients and Methods
The present clinical non-randomized and non-controlled study was conducted on 201 kidney transplant patients in Shar teaching Hospital in Sulaimani, Kurdistan region-Iraq, from April 2020 to April 2021. The patients had received tacrolimus and Cyclosporine as immunosuppression drugs. Required data were collected from the patients through their hospital records and direct interviews with them. The collected data were analyzed through Statistical Package for Social Science (version 22.0).
Results
Most patients (60.7%) were aged 19-45 and males (70.6%). Most of them did not know the cause of chronic kidney failure (41.3%), focal segmental glomerulosclerosis in 14.4%, and diabetes mellitus in 12.4%. Most of the donors were non-related (90.5%). Induction treatment was anti-thymocyte globulin for most of them (76.6%), and treatment after transplant, mycophenolate mofetil, Cyclosporine and prednisolone in 75% of them. Acute cellular rejection was the most frequent complication after the transplant (23.4%). Tremor and new onset of diabetes were the most frequent side effects of tacrolimus; however, hirsutism, hyperkalemia, acne, hypertension, and hyperlipidemia are the most frequent side effects Cyclosporine. More patients on Tacrolimus than Cyclosporine developed new onset of diabetes (7.5%). However, serum uric acid (p<0.001), serum cholesterol (p<0.001), and serum triglyceride (p=0.01) levels elevate more with Cyclosporine group patients. Moreover, drug change has a significant association with haemoglobin level (HGB) (p<0.001) and serum triglyceride (p<0.001) in those group drug was changed to tacrolimus.
Conclusion
Similar rejection was obtained by using Tacrolimus and Cyclosporine within the first year after kidney transplant in low immunological risk patients; however, acute cellular rejection was less with the TAC group. It is less expensive than Cyclosporine in our region, but Cyclosporine is more available in the hospital.
KEYWORDS
Kidney transplantation, Chronic kidney disease, Anti-thymocyte globulin, Tacrolimus, Cyclosporine.
References
1. Alberici F, Delbarba E, Manenti C, Econimo L, Valerio F, Pola A, et al. Management of patients on dialysis and with kidney transplantation during the SARS-CoV-2 (COVID-19) pandemic in Brescia, Italy. Kidney International Reports. 2020; 5(5), 580–585.
2. Malekshahi A, MortezaNejad H.F, Taromsari M.R. et al. An evaluation of the current status of kidney transplant in terms of the type of receipt among Iranian patients. Ren Replace Ther. 2020; 6, 66. https://doi.org/10.1186/s41100-020-00314-8
3. Neuwirt H, Rudnicki M, Schratzberger P, Pirklbauer M, Kronbichler A, Mayer G. Immunosuppression after renal transplantation. Memo. 2019; 12(3), 216–221.
4. Fuchs U, Klein S, Zittermann A, et al. Incidence of malignant neoplasia after heart transplantation-a comparison between Cyclosporine and tacrolimus. Ann Transplant. 2014; 19:300–304.
5. Ravanshad Y, Azarfar A, Ravanshad S, Naderi Nasab M, Ghasemi A, et al. A comparison between tacrolimus and Cyclosporine as immunosuppression after renal transplantation in children, A meta-analysis and systematic review. Iranian Journal of Kidney Diseases. 2020; 14(2), 145–152.
6. Liu J.Y, You R.X, Guo M, Zeng L, Zhou P, Zhu L, et al. Tacrolimus versus Cyclosporine as primary immunosuppressant after renal transplantation: A meta-analysis and economics evaluation. American Journal of Therapeutics. 2016; 23(3), e810–e824.
7. Heemann U, Abramowicz D, Spasovski G, et al.; European Renal Best Practice Work Group on Kidney Transplantation. Endorsement of the Kidney Disease Improving Global Outcomes (KDIGO) guidelines on kidney transplantation: A European Renal Best Practice (ERBP) position statement. Nephrol Dial Transplant. 2011; 26: 2099–2106.
8. Bang J.B, Lee S.H, Oh C.K, Ju M.K, Yu H.C. Clinical study of standard- versus reduced-dose tacrolimus combined with generic mycophenolate mofetil in DE Novo kidney transplantation: A prospective randomized trial. Transplantation. 2020; 104(S3), S618–S618.
9. Lim WH, Chadban SJ, Clayton P Et al. Human leukocyte antigen mismatches associated with increased risk of rejection, graft failure, and death independent of initial immunosuppression in renal transplant recipients. Clin Transplant. 2012; 26: E428–E437
10. Webster AC, Ruster LP, McGee R, et al. Interleukin 2 receptor antagonists for kidney transplant recipients. Cochrane Database Syst Rev 2010; CD003897.
11. Maglakelidze N, Pantsulaia T, Tchokhonelidze I, Managadze L, Chkhotua A. Assessment of health-related quality of life in renal transplant recipients and dialysis patients. Transplantation Proceedings. 2011; 43(1), 376–379. DOI: 10.1016/j.transproceed.2010.12.015
12. Nasri H, Rafieian-Kopaei M. Diabetes mellitus and renal failure: Prevention and management. Journal of Research in Medical Sciences: The Official Journal of Isfahan University of Medical Sciences. 2015; 20(11), 1112–1120. DOI: 10.4103/1735-1995.172845.
13. Gheith O, Farouk N, Nampoory N, Halim M.A, Al-Otaibi T. Diabetic kidney disease: worldwide difference of prevalence and risk factors. Journal of Nephropharmacology. 2016; 5(1), 49–56.
14. Dana S, Alaa A, Kosar M, Ibrahim M. Demographic and Characteristic Distribution of End-Stage Renal Failure in Sulaimani Governorate, Kurdistan Region, Iraq. International Journal of Medicine Research professionals. 2017; DOI: 10.21276/ijmrp.2017.3.1.037.
15. Kim J. S, Han B. G, Choi S. O, Cha S.K. Secondary focal segmental glomerulosclerosis: From podocyte injury to glomerulosclerosis. BioMed Research International. 2016; 1630365.
16. Malvezzi P, Jouve T, Rostaing L. Induction by anti-thymocyte globulins in kidney transplantation: a literature review and current usage. Journal of Nephropathology. 2015; 4(4), 110–115. DOI: 10.12860/jnp.2015.21.
17. Vacha M, Gommer J, Rege A, et al. Effects of Ideal Versus Total Body Weight Dosage of Rabbit Antithymocyte Globulin on Outcomes of Kidney Transplant Patients with High Immunologic Risk. Experimental and Clinical Transplantation. 2016; 14(5), 511 - 517.
18. Pishtewan H, Al Bazzaz. Kidney transplantation in Erbil, Iraq. 2010; 21(2), 359 -362.
19. Garcia P, Huerfano M, Rodriguez M, Caicedo A, Berrio F, Gonzalez C. Acute rejection in renal transplant patients of a hospital in Bogota, Colombia. International Journal of Organ Transplantation Medicine. 2016; 7(3), 161–166.
20. Kim D.G, Choi H.Y, Kim H.Y, Lee E.J, Huh K.H, et al. Association between post-transplant serum uric acid levels and kidney transplantation outcomes. PloS One. 2018; 13(12), e0209156. https://doi.org/10.1371/journal.pone.0209156
21. Kanbay M. et al., Influence of Cyclosporine and Tacrolimus on Serum Uric Acid Levels in Stable Kidney Transplant Recipients. Transplantation Proceedings. 2005; 37, 3119–3120.
22. Mahmood, Mohammed & Rasheed, Jawad & Hussein, Mustafa. (2020). Comparison of side effects between Cyclosporine and tacrolimus as immunosuppressive therapy in Iraqi kidney transplant recipients. Annals of Tropical Medicine and Public Health. 23. 10.36295/ASRO.2020.231349.
23. Azarfar A et al. Comparison of tacrolimus and Cyclosporine for immunosuppression after renal transplantation: An updated systematic review and meta-analysis. Saudi Journal of Kidney Diseases and Transplantation. 2018; 29. 1376. 10.4103/1319-2442.248292.
© The Authors, published by University of Sulaimani, College of Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License.
Page updated
Report abuse